Work Here?
Overview
Rejuvenate Bio develops gene therapies to treat aging and age-related diseases. It translates Harvard-affiliated research into therapies that modify genes, using cellular reprogramming to target aging pathways. The company funds early work with venture capital and plans to partner with pharmaceutical companies, license technologies, or sell approved therapies after regulatory approval. Its goal is to bring gene therapies to market that extend healthspan and improve quality of life for elderly people and those with chronic conditions.
About Rejuvenate Bio
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$27.6M
Headquarters
San Diego, California
Founded
2019
Get referred to Rejuvenate Bio
See people who can refer or advise you
Simplify's Take
What believers are saying
- June 2026 Merck Animal Health partnership validates the platform with a strategic pharma name.
- Rejuvenate Bio raised $6 million and extended veterinary development without obvious runway shock.
- Patsnap shows one IND application and multiple preclinical programs, preserving pipeline optionality.
What critics are saying
- June 2026 funding was only $6 million, signaling dependence on repeated dilutive raises.
- Most programs remain preclinical or IND-stage; human commercialization stays years away.
- Merck collaboration centers on animal health, leaving the human-aging thesis commercially unproven.
What makes Rejuvenate Bio unique
- Harvard/George Church origin and multi-gene longevity platform differentiate Rejuvenate Bio from single-target biotech peers.
- Merck Animal Health joined a June 2026 financing and R&D collaboration.
- Pipeline spans canine MVD, obesity, lipodystrophy, and human aging programs.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$27.6M
Below
Industry Average
Funded Over
6 Rounds
Industry standards
Growth & Insights and Company News
6 month growth
↓ -5%1 year growth
↓ -5%2 year growth
↓ -5%For best search results, use the search terms first and then apply the filters. Search results are downloadable for 10,000 or fewer records.
Rejuvenate Bio secures new funding and Merck partnership in anti-aging gene therapy push. Rejuvenate Bio lands fresh investment and a Merck partnership, signaling growing pharma confidence in gene therapy approaches to aging. 2026-06-24 Rejuvenate Bio, a longevity-focused biotech developing gene therapy interventions targeting the biology of aging, has secured new funding alongside a strategic partnership with pharmaceutical giant Merck, according to reporting from Longevity.Technology. The announcement marks one of the more significant validation moments for the aging gene therapy field in recent months, with a major established pharma player now formally aligned with a company working at the frontier of biological age reversal. For industry observers, the Merck partnership carries particular weight. Large pharmaceutical companies have historically maintained a cautious distance from longevity biotechs, preferring to watch the science mature before committing resources. A named partnership with Merck suggests that calculus is shifting. Whether the collaboration involves co-development, licensing arrangements, or research access remains to be detailed publicly, but the signal it sends to the broader agetech and longevity investment community is difficult to overstate. Rejuvenate Bio has built its platform around gene therapy approaches that aim to address aging at a systemic level rather than targeting individual age-related diseases in isolation. The company's scientific foundation draws on work exploring how specific gene interventions can influence biological processes associated with aging across multiple organ systems simultaneously. This systems-level framing has distinguished Rejuvenate Bio from many peers in the longevity biotech space who focus on single-pathway or single-disease approaches. The timing of this announcement fits within a broader pattern of accelerating institutional interest in longevity biotechnology through 2025 and into 2026. Funding rounds across the sector have grown in both frequency and scale, and the entry of established pharmaceutical partners into formal collaborations represents the next logical phase of market maturation. For agetech professionals working in adjacent areas - from senior living technology to AI-enabled care platforms - the continued validation of the longevity biotech space reinforces the overall investment narrative around aging as a defining market category. The practical implications for near-term clinical translation are still developing. Gene therapy approaches to aging face meaningful regulatory and safety questions that will take years of clinical work to resolve. However, partnerships like the one announced between Rejuvenate Bio and Merck typically accelerate that process by bringing additional scientific infrastructure, regulatory experience, and capital to bear on exactly those challenges. As the agetech industry continues to expand across both care technology and longevity science, deals of this nature serve as important connective tissue between the cutting edge of research and the commercial pathways that will eventually deliver interventions to aging populations at scale. Get the AgeTech Digest Funding rounds, product launches, and industry moves - every week, free.
Lifespan portfolio company Rejuvenate Bio closes $6 million financing and R&D collaboration with Merck Animal Health. Jun 11, 2026, 09:59 ET Milestone financing and R&D collaboration advances gene therapy programs targeting chronic and age-related diseases in companion animals. NORWALK, Conn., June 11, 2026 /CNW/ - Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, congratulates its portfolio company Rejuvenate Bio on the successful close of a $6 million financing round and the announcement of a strategic research and development collaboration with Merck Animal Health. The financing round was led by VCapital, with participation from Merck Animal Health, Connecticut Innovations, and Digitalis. Proceeds will support continued advancement of Rejuvenate Bio's gene therapy platform and pipeline, including treatments designed to address chronic and age-associated diseases in companion animals. Alongside the financing, Rejuvenate Bio and Merck Animal Health have entered into a strategic R&D collaboration focused on advancing a novel gene therapy program in animal health, leveraging Rejuvenate Bio's proprietary platform technologies and translational expertise. Andrew Worden, Founding Partner at Lifespan Vision Ventures stated, "We are proud to see Rejuvenate Bio reach this important milestone. The confidence shown by Merck Animal Health - both as an investor and a collaborator - speaks to the strength of the team and the promise of their science. Lifespan Vision Ventures is delighted to continue supporting their mission to address some of the most significant unmet needs in companion animal and human health." Rejuvenate Bio is developing gene therapies aimed at extending healthy lifespan and treating chronic diseases across both veterinary and human health applications. The company's approach focuses on modifying biological pathways associated with aging through targeted genetic interventions. About Lifespan Vision Ventures Lifespan Vision Ventures is a global venture capital firm investing in early-stage biotechnology companies developing breakthrough technologies to prevent and treat age-related diseases. The firm partners with visionary founders advancing science-driven solutions that promote healthy aging and extend human healthspan. About Rejuvenate Bio Rejuvenate Bio is a biotechnology company dedicated to developing novel gene therapies for chronic age-related diseases. Rejuvenate Bio has built a gene therapy pipeline with huge potential in chronic disease by utilizing clinically validated gene targets and a delivery approach that ensures well tolerated, durable expression. Founded on scientific research developed at the Wyss Institute at Harvard Medical School, Rejuvenate Bio has developed groundbreaking therapies to treat chronic age-related disease in both humans and animals. The company is headquartered in San Diego, CA. SOURCE LifeSpan Vision Ventures
Rejuvenate Bio announces $6 million financing and strategic R&D collaboration with Merck Animal Health. Funding will support advancement of gene therapy programs in animal health and longevity science SAN DIEGO-(BUSINESS WIRE)-Rejuvenate Bio, a biotechnology company developing gene therapies for age-related and chronic diseases, today announced the closing of a $6 million financing round led by VCapital, with participation from Merck Animal Health, Kendall Capital Partners, Connecticut Innovations and Digitalis. In addition to the financing, Rejuvenate Bio and Merck Animal Health have entered into a strategic research and development collaboration focused on advancing a novel gene therapy program in animal health. The funding will support continued development of Rejuvenate Bio's platform and pipeline, including therapies designed to address chronic and age-associated diseases in companion animals. "We believe gene therapy has the potential to fundamentally transform the treatment of chronic disease and age-related conditions," said Daniel Oliver, CEO & Co-Founder, Rejuvenate Bio. "This financing and strategic collaboration with Merck Animal Health validates both the strength of our platform and the growing interest in innovative approaches to animal health. We are excited to work alongside leading investors and industry partners to accelerate the development of transformative therapies for veterinary medicine." The collaboration with Merck Animal Health will focus on advancing a targeted gene therapy program leveraging Rejuvenate Bio's platform technologies and translational expertise. "This investment reflects our ongoing commitment to partner with leading innovators to advance new capabilities in animal health," said Jim McIntyre, head of business development, Merck Animal Health. "We are eager to partner with Rejuvenate Bio to explore potentially transformative technologies and therapeutics to market that address important unmet needs in veterinary medicine." Rejuvenate Bio is developing gene therapies aimed at extending healthy lifespan and treating chronic disease through targeted biological interventions. The company's platform combines advances in gene delivery, translational biology, and longevity science to develop therapies for companion animals and, ultimately, human health applications.
Rejuvenate Bio, a biotechnology company developing gene therapies for age-related and chronic diseases, has raised $6 million in a funding round led by VCapital. Merck Animal Health, Kendall Capital Partners, Connecticut Innovations and Digitalis also participated. Alongside the financing, Rejuvenate Bio and Merck Animal Health have entered into a strategic research and development collaboration to advance a novel gene therapy programme in animal health. The funding will support development of therapies for chronic and age-associated diseases in companion animals. The collaboration will leverage Rejuvenate Bio's platform technologies, which combine advances in gene delivery, translational biology and longevity science. The company's pipeline targets chronic disease using clinically validated gene targets and aims to eventually extend applications to human health.
There are no jobs for Rejuvenate Bio right now.
Find jobs on Simplify and start your career today
About Rejuvenate Bio
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$27.6M
Headquarters
San Diego, California
Founded
2019
There are no jobs for Rejuvenate Bio right now.
Find jobs on Simplify and start your career today